AOP Health
AOP Health is a biopharmaceutical company focused on the development and distribution of drugs and treatment approaches for rare diseases and metabolic disorders. It engages in research, development, production and distribution of medicines and niche generics across hematology, oncology, cardiology, pulmonology, neurology, psychiatry, and metabolic diseases. The company also provides metabolic disorder services addressing conditions such as atrial fibrillation, pulmonary arterial hypertension, chemotherapy-induced nausea, septic shock, critical care, and other hematology-oncology and metabolic conditions.
1 past transactions
Shield Therapeutics
Post in 2023
Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.